How Efficacious Must a COVID-19 Coronavirus Vaccine be to Prevent or Stop an Epidemic by Itself

Author:

Bartsch Sarah M.,O’Shea Kelly J.,Ferguson Marie C.,Bottazzi Maria Elena,Cox Sarah N.,Strych Ulrich,McKinnell James A.,Wedlock Patrick T.,Siegmund Sheryl S.,Hotez Peter J.,Lee Bruce Y.

Abstract

AbstractBackgroundGiven the continuing coronavirus disease 2019 (COVID-19) pandemic and much of the U.S. implementing social distancing due to the lack of alternatives, there has been a push to develop a vaccine to eliminate the need for social distancing.MethodsIn 2020, we developed a computational model of the U.S. simulating the spread of COVID-19 coronavirus and vaccination.ResultsSimulation experiments revealed that when vaccine efficacy exceeded 70%, coverage exceeded 60%, and vaccination occurred on day 1, the attack rate dropped to 22% with daily cases not exceeding 3.2 million (reproductive rate, R0, 2.5). When R0 was 3.5, the attack rate dropped to 41% with daily cases not exceeding 14.4 million. Increasing coverage to 75% when vaccination occurred by day 90 resulted in 5% attack rate and daily cases not exceeding 258,029when R0 was 2.5 and a 26% attack rate and maximum daily cases of 22.6 million when R0 was 3.5. When vaccination did not occur until day 180, coverage (i.e., those vaccinated plus those otherwise immune) had to reach 100%. A vaccine with an efficacy between 40% and 70% could still obviate the need for other measures under certain circumstances such as much higher, and in some cases, potentially unachievable, vaccination coverages.ConclusionOur study found that to either prevent or largely extinguish an epidemic without any other measures (e.g., social distancing), the vaccine has to have an efficacy of at least 70%.

Publisher

Cold Spring Harbor Laboratory

Reference80 articles.

1. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles

2. A systems approach to vaccine decision making;Vaccine,2017

3. Infection control measures for norovirus: a systematic review of outbreaks in semi-enclosed settings

4. Heidelberg Institute for Geoinformation Technology. Mapping COVI-19 Research. 2020 [cited 2020 May 11]; Available from:

5. The COVID-19 vaccine development landscape;Nat Rev Drug Discov,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3